Formycon AG

Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance

Formycon AG: Dr. Stefan Glombitza, buy

Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024

Convincing overall performance – Formycon reports preliminary results for the financial year 2023 and exceeds forecast

Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)

Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

Gedeon Richter becomes strategic investor of Formycon via equity investment

Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor

Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023

Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference

Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®

Formycon announces participation in international Investor Conferences in Q1/2024

Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration

Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Formycon publishes nine-month results for 2023

Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences

Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States

Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Formycon reports successful first half of 2023

Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)

Formycon hosts conference call on financial and earnings position for H1 2023

Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar

Formycon reports on the regular Annual General Meeting

Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)

Formycon reports results for the first quarter 2023

Formycon Announces Participation in International Investor Conferences in Q2/2023

Formycon publishes results for financial year 2022